advertisement
Congress moves to allow generic biologic meds
Two members of Congress have introduced a bill that would allow the U.S. Food and Drug Administration (FDA) to approve generic versions of biologic medications. The legislation would provide brand-name biotech companies with at least 12 years--and possibly an additional 2.5 years--of market exclusivity before generic versions of their drugs could be sold on the market. The bill also requires clinical trials for generic versions of biotech medications, although the FDA could waive this requirement.
(kaisernetwork.org) UPDATED 03/17/2008Click here to read the full story
Conditions: | Crohn's disease - 133 Articles | rheumatoid arthritis (RA) - 259 Articles Treatments: | TNF alpha blockers - 59 Articles | tumor necrosis factor - 59 Articles
Helpful?
advertisement
